Background: We investigated differences in immune restoration and onset of new AIDS-defining events on combination antiretroviral therapy (cART) among HIV type-1 (HIV-1)-infected patients of different regional origin now living in the Netherlands. Methods: Treatment-naive adults reaching plasma viral load (pVL)<400 copies/ml within 9 months of starting cART were selected from the Netherlands ATHENA cohort. CD4 + T-cell response on cART was determined over 7 years using mixed models. CD4 + T-cell counts were excluded from the analyses at the first of two consecutive measurements of pVL≥400 copies/ml following prior suppression to <400 copies/ml. Multivariate analyses + T-cell counts than men from WN, they continued to lag behind and had lower absolute CD4 + T-cell counts after 7 years of cART. Furthermore, cumulative tuberculosis incidence after 7 years of cART was higher in SSA compared with WN (4.5% versus 0.5%, hazard ratio 5.08, 95% confidence interval 2.22-11.60). Conclusions: HIV-1-infected immigrants from SSA have blunted immune restoration on fully suppressive cART and should be identified at an earlier disease stage. Our results call for more intensive screening for both latent and active tuberculosis in these patients.
Introduction
immunological response in immigrants from SSA was decreased compared with patients from Western Europe. By contrast, smaller studies have reported similar immunological responses compared to indigenous patients, despite a poorer virological response, possibly as a result of lower adherence [11, 12] .
In HIV-1-infected patients able to continue cART, sustained immunological responses can be maintained for long periods [13] [14] [15] [16] . Evidence for a robust CD4 + T-cell response in patients originating from SSA, Asia and Latin America was found in a multicohort collaboration investigating CD4 + T-cell response during 5 years of cART [17] .
The present study sought to further investigate potential differences in long-term CD4 + T-cell response to cART among HIV-1-infected previously untreated virologically suppressed patients from Western Europe/ North America (WN), SSA, Southeast Asia (SEA), Latin America/Caribbean (LAC) and other regions now living in the Netherlands, and to determine whether a possible decreased immunological response in any of these groups translates into poorer clinical outcome.
Methods

Patients
The ATHENA cohort is an observational cohort study in the Netherlands with continuing enrolment of HIV-1-infected individuals [9] . For this study, we selected all patients above 16 years of age who were antiretroviraltherapy-naive and who started cART after January 1996. Patients were subdivided according to the geographical region they originated from, including WN, SSA, SEA, LAC or elsewhere. Patients were excluded if cART did not suppress plasma HIV-1 RNA to <400 copies/ml within 9 months following the start of cART, leaving 6,057 patients eligible for the analysis.
Definitions
Detectable HIV-1 viraemia was defined as two consecutive viral load measurements ≥400 copies/ml. Chronic hepatitis C was defined as positive plasma HCV RNA, or HCV-positive antibodies if HCV RNA was missing. Chronic hepatitis B was defined as positive hepatitis B surface antigen.
Statistical analyses
We investigated the maximum capacity of CD4 + T-cell restoration (that is, changes in CD4 + T-cell count over time from the CD4 + T-cell count at initiation of cART) in continuously suppressed patients and occurrence of new AIDS-defining events during cART. Patients were followed from the start of cART until the date of the last available CD4 + T-cell count or on 1 February 2009, whichever occurred first. We considered all CD4 + T-cell counts measured while patients were actually using cART. CD4 + T-cell counts were excluded from the analyses after treatment interruptions >30 days or at the first of two consecutive HIV-1 RNA measurements ≥400 copies/ml following prior suppression to <400 copies/ml, whichever occurred first. Change in treatment regimens for reasons other than virological failure was allowed. Median changes in CD4 + T-cell counts were compared among patients using the Mann-Whitney U test. To analyse changes in long-term CD4 + T-cell response from the start of cART, mixed effect models were used. Mean changes in CD4 + T-cell count were calculated separately for the following time periods: 0 to <6 months, 6 months to <3 years, 3 to <5 years, and 5 to <7 years after starting cART. Models included random slopes for these time periods for each patient. The methods applied for estimating maximum CD4 + T-cell recovery are fairly robust to bias resulting from loss to follow-up, as they are based on the missing at random assumption, which allows the probability of loss to follow-up to be related to past CD4 + T-cell counts and region of origin. Kaplan-Meier curves and time-updated Cox regression models were used to analyse time from the start of cART to a CD4 + T-cell count of 500 cells/mm³ (in patients starting cART with CD4 + T-cell counts <500 cells/mm³) and time to new AIDSdefining events (tuberculosis, other opportunistic infections and AIDS-defining malignancies). If the end point was not reached during follow-up, then follow-up time of the analyses ended at the last available CD4 + T-cell count measurement. Analyses were adjusted for gender, age, CD4 + T-cell count and HIV-1 RNA prior to the start of cART, HCV and/or HBV coinfection, transmission risk group, cumulative exposure to protease inhibitors (PIs) or non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs), cumulative exposure to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), AIDS diagnosis before starting cART and region of origin. Patients were allowed to switch regimens during follow-up, but only for reasons other than virological failure. NRTIs were categorized as zidovudine (AZT)/ lamivudine (3TC) regimens, tenofovir disoproxil fuma- 
Results
Patient characteristics
The baseline characteristics of the 6,057 selected patients are shown in Table 1 . Most patients (65%) were from WN, with 16% from SSA, 4% from SEA, 11% from LAC and 3% from elsewhere. The median follow-up after starting cART was 3.2 years. There were 3,135 patients with at least one CD4 + T-cell count measurement between 3 and <5 years after starting cART, and the median number of measurements was 5 (interquartile range [IQR] 3-6). There were 1,935 patients with at least one CD4 + T-cell count measurement between 5 and <7 years after starting cART, the median being 7 measurements (IQR [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 
CD4
+ T-cell count trajectories after antiretroviral therapy initiation 
Regression models
Mixed models predicting mean CD4 + T-cell increases are shown in Table 2 and Figure 2 . The model fit was good when comparing predicted with observed data. Models were adjusted for gender, age, CD4 + T-cell count and HIV-1 RNA prior to cART, HCV and/or HBV coinfection, transmission risk group, cumulative exposure to PIs and/or NNRTIs, cumulative exposure of NRTIs, AIDS diagnosis before starting cART and region of origin.
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396 (10) 125 (13) 18 (8) 71 (10) 21 (11 For patients from SSA, the estimated CD4 + T-cell increase was significantly lower compared with patients from WN in the first 6 months of cART (36 cells/mm³ less; P<0.0001). As a result of this initial delay in CD4 + T-cell restoration, in addition to the lower CD4 + T-cell counts at which cART was initiated, estimated median CD4 + T-cell counts in patients from SSA were 70 cells/ mm 3 lower after 7 years of follow-up compared to WN patients. No difference in CD4 + T-cell response was found between WN patients and those from SEA, LAC or other geographical regions, nor was there a statistical interaction between region of origin and gender.
Men having sex with men, patients with an AIDS diagnosis before starting cART, and patients <35 years of age had higher CD4 + T-cell increases in the first 6 months after starting cART, compared with older patients. Patients starting cART with HIV-1 RNA<100,000 copies/ml compared with ≥100,000 copies/ml and baseline CD4 + T-cell counts <200 cells/ mm³ compared with 200-350 cells/mm 3 had lower CD4 + T-cell increases during the first 6 months of cART. In subsequent years, patients with CD4 + T-cell counts <200 cells/mm 3 had higher CD4 + T-cell increases, partly making up for the initial delay in CD4 + T-cell restoration (Table 2 ). Patients treated with boosted PI-containing cART regimens had higher CD4 + T-cell increases compared with patients on NNRTI-based regimens: 26 cells/mm³ higher between 0-<6 months (P<0.0001), 17 cells/mm³ higher between 6 months and <3 years (P<0.0001) and 9 cells/mm³ higher between 3-<5 years (P=0.04). Compared with patients using an AZT/3TC-containing backbone, patients using TDF-containing regimens (not TDF/didanosine) had higher estimated mean CD4 + T-cell increases in the first 6 months (16 cells/mm³ greater increase), and patients using ABC-containing regimens had higher CD4 + T-cell increases in both the first 6 months and between 6 months and <3 years (47 cells/mm³ per year [23 cells/mm³ per 6 months] and 12 cells/mm³ per year greater increase, respectively).
Time to reaching CD4 + T-cell count of 500 cells/mm³
Using Cox regression models adjusted for CD4 + T-cell and plasma viral load at the start of cART, age, sex, prior AIDS diagnosis and route of transmission, we found that among patients starting cART with CD4 + T-cell counts <500 cells/mm³ (n=5,900), those from SSA were significantly less likely to reach 500 cells/mm³ compared with WN patients (hazard ratio [HR] 0.71, 95% CI 0.63-0.80). Female SSA patients were more likely to reach 500 cells/mm³ than males (HR 1.45, 95% CI 1.30-1.62). No interaction between region of origin and gender was found.
Progression to AIDS
After the start of cART, 523 new AIDS-defining events (excluding HIV-1 dementia and HIV-1 wasting) were diagnosed during follow-up in 483 patients on fully suppressive cART. Of those events, 58 were tuberculosis, 298 were other opportunistic infections and 167 were AIDS-defining malignancies. The median time to tuberculosis was 194 days (IQR 59-527), to other opportunistic infections was 63 days (IQR 18-227), and to AIDS-defining malignancies was 99 days (IQR 35-259). A total of 29 (50%) tuberculosis diagnoses occurred within 6 months of starting cART, compared with 213 (71%) other opportunistic infections and 106 (63%) AIDS-defining malignancies. The median CD4 + T-cell count at diagnosis was 218 cells/mm 3 (IQR 127-360) for tuberculosis, 160 cells/ml (IQR 50-307) for opportunistic infections, and 180 cells/ml (IQR 90-360) for AIDS-defining malignancies.
Kaplan-Meier estimates for the first new AIDSdefining events (that is, excluding recurrent AIDSdefining events) after starting cART for patients stratified according to region of origin are shown in Figure 3 . Tuberculosis was observed more frequently in patients from SSA compared with patients of WN origin (3.0% and 0.4%, respectively; P<0.0001). No significant differences were found in time to opportunistic infections and AIDS-defining malignancies among patient groups. Kaplan-Meier estimates for tuberculosis were significantly higher for patients from SSA compared with patients from WN within 6 months (1.5% versus 0.2%), 3 years (3.5% versus 0.4%) and 7 years (4.5% versus 0.5%) after starting cART (P<0.0001).
In multivariate Cox regression models, both the latest CD4 + T-cell count and the region of origin were independent predictors for tuberculosis. Compared with patients from WN, time to tuberculosis was shorter in patients from SSA (HR 5.08, 95% CI 2. 22-11.60 
Discussion
Findings
Using this large national observational cohort, we aimed to describe the maximum capacity of restoration of the immune system in HIV-1-infected patients from various regions of origin who had achieved virological suppression within 9 months of having started cART and who had sustained suppression during follow-up. Our analyses will thus probably overestimate the true effect of cART on CD4 + T-cell response in all patients starting cART. Compared with patients from WN, patients from SSA had a significantly lower estimated annual increase in CD4 + T-cell count in the first 6 months after starting cART. These findings were independent from CD4 + T-cell count prior to initiation of cART. Additionally, SSA patients, and particularly males in this group, started cART with a lower median CD4 + T-cell count and were less likely to reach 500 cells/mm³ compared to WN males.
To investigate the clinical significance of differences in immune restoration between patients originating from different geographical regions, we evaluated the occurrence of new AIDS-defining events after the start of cART in these groups. We investigated only first-time events that occurred during follow-up. We found that patients from SSA experienced more tuberculosis than WN patients, but did not experience a higher rate of the other opportunistic infections or AIDS-defining malignancies. Of the new tuberculosis cases diagnosed in SSA patients after starting cART, 50% occurred within 6 months after starting cART and, as such, were potentially 'unmasking' immune reconstitution inflammatory syndrome (IRIS) events rendered clinically manifest as a result of immune reconstitution. Of note, these early tuberculosis events, either independently or by their association with more treatment toxicity or the need to temporarily interrupt treatment, might have contributed to a lack of CD4 + T-cell increases in the first 6 months after initiating cART in these patients. Of note, however, one-half of tuberculosis diagnoses occurred >6 months after starting cART.
In adjusted Cox regression models, we found that the occurrence of tuberculosis was independently associated with both SSA region of origin as well as having a CD4 + T-cell count <200 cells/mm³. Thus the higher incidence of tuberculosis in SSA patients can partly be explained by higher prevalence of latent infection in combination with higher rates of reactivation of latent tuberculosis caused by more profound immunodeficiency. Moreover, compared with people from other regions, they might be at a higher re-exposure risk of tuberculosis through visits to their home country or through contact in the Netherlands with fellow immigrants arriving from SSA. Although several studies have found a decrease in tuberculosis incidence rates in HIV-1-infected patients using cART [18] [19] [20] [21] , even individuals responding well to cART with relatively preserved CD4 + T-cell counts might still remain at risk for tuberculosis over a prolonged life span [22] [23] [24] . The incidence of tuberculosis in the cART era can be reduced by using tuberculin skin testing in low transmission countries, which is especially important in patients originating from regions with high tuberculosis infection rates [25] . Screening for both latent and active tuberculosis in all immigrants from these countries and utilizing isoniazid preventive therapy in case of latent tuberculosis is recommended [26] .
Consequences of late entry into patient care
CD4
+ T-cell count at the time of cART initiation is an important determinant of morbidity and mortality [27] [28] [29] [30] [31] . In the Netherlands, HIV-1-infected immigrants from SSA, especially males, usually present with relatively low CD4 + T-cell counts. Their life-expectancy might be compromised by this late presentation. A mathematical simulation model using ATHENA data suggests that mortality rates in the first 3 years of cART can be reduced if patients would present earlier when they still have higher CD4
+ T-cell counts [32] . Unfortunately, a substantial number of immigrants from SSA do not have health insurance and have limited access to care, which contributes to the late presentation. Women from SSA who live in the Netherlands are frequently enrolled in HIV screening programmes during pregnancy [8] , which might explain why women from SSA tend to start cART with less delay and higher CD4 + T-cell counts than men from SSA.
+ T-cell increase in patients from SSA
Compared with patients from WN, patients from SSA started cART at lower CD4 + T-cell counts, showed lower CD4 + T-cell increases in the first 6 months of starting cART and had lower absolute CD4 + T-cell counts after 7 years of cART. CD4 + T-cell increases after 6 months were similar between patients from WN and patients from elsewhere. Additionally, as these patients were less likely to reach 500 cells/mm³, the delayed immune reconstitution ultimately has a long-term effect on life expectancy [8] , although it is unknown whether CD4 + T-cell levels required for a similar life expectancy to healthy individuals differ between patients from SSA and WN. One large study investigating CD4 + T-cell increases in patients from resource-limited settings found robust CD4 + T-cell restoration after 5 years of cART [17] . Because these patients were not all virologically suppressed, and they were not compared by region of origin, that study is difficult to compare with ours. Smaller studies, comparing regions, found that although virological response was poorer in African patients during the first 2 years of cART, their antiretroviral treatment was equally successful in terms of immune recovery [11, 12] .
Possible causes of lower CD4
Mean CD4
+ T-cell counts in HIV-1-seronegative individuals from Tanzania, Ethiopia and Kenya are reportedly lower compared to HIV-1-seronegative Dutch patients [33] [34] [35] [36] [37] . Seropositive untreated patients from Ethiopia with lower baseline CD4 + T-cell counts experience a slower decrease in CD4 + T-cells than seropositive Dutch patients, but demonstrate no difference in time to AIDS [38] . A slower decrease in CD4 + T-cell counts in untreated HIV-1-infected immigrants from Africa was likewise reported by the Swiss HIV Cohort Study [39] . Viewed in this light, the blunted increase in absolute CD4 + T-cell counts might be explained by the lower normal values of CD4 + T-cell counts in SSA patients: although the absolute increase in CD4 + T-cell counts is lower, the CD4 + T-cell increase might be entirely proportional relative to the different normal values for the investigated populations. Unfortunately, CD4 + T-cell percentages are not available in the ATHENA cohort. Alternative explanations for our findings might reflect the effect of differences in viral subtypes [40] [41] [42] , host genetic factors [43] and environmental variability [44] among patients.
Limitations
Because ATHENA is an observational cohort study, we had to exclude a substantial number of patients because of missing baseline or follow-up CD4 + T-cell counts. Patients excluded from the analyses were more likely to die or to become lost before a follow-up CD4 + T-cell count could be measured. Our analyses might therefore overestimate the true effect of cART on CD4 + T-cell response in all patients starting cART. The occurrence of IRIS was not investigated prospectively in this cohort and the effect IRIS might have had on delayed immune reconstitution can not be determined. We emphasize that our findings apply only to those patients who survived, remained in care with follow-up CD4 + T-cell counts and had a good virological response to cART.
Conclusions
More efforts should be made to identify HIV-1-infected patients from SSA at an earlier stage of HIV-1 infection, thereby allowing them to access the healthcare system at a higher CD4 + T-cell count, and improving their chance of optimal CD4 + T-cell increases during cART. Our results also call for more intensive screening for both latent and active tuberculosis in all immigrants from these countries, and for utilizing isoniazid preventive therapy more often, including in those who have already started cART.
